Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
Zhou J. et al, (2025), EClinicalMedicine
A Mendelian randomization study of the effect of body mass index on 52 causes of death among 125 000 Mexican adults with admixed ancestry.
Gnatiuc Friedrichs L. et al, (2025), Int J Epidemiol, 54
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial.
Lamikanra AA. et al, (2025), Br J Nutr, 1 - 18
Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY P. et al, (2025), The Lancet Infectious Diseases
Correction: Optimum dose of vitamin D for disease prevention in older people: BEST-D trial of vitamin D in primary care.
Hin H. et al, (2025), Osteoporos Int
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY PW. et al, (2025), The Lancet Infectious Diseases
Prediabetes and risk of all-cause and cause-specific mortality: a prospective study of 114,062 adults in Mexico City.
Fermín-Martínez CA. et al, (2025), J Clin Endocrinol Metab
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Type 2 diabetes and cause-specific mortality in Mexico City: a Mendelian randomisation analysis
EMBERSON J. et al, (2025), The Lancet Regional Health - Americas
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2025), EClinicalMedicine, 81
Balancing the risk of major bleeding against vascular disease risk in people without atherosclerotic disease.
Hammami I. et al, (2025), Heart
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
EMPA-KIDNEY Collaborative Group None. et al, (2025), N Engl J Med, 392, 777 - 787
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.
Mitchell J. et al, (2025), Nat Commun, 16
Polygenic prediction of coronary artery disease among 130,000 Mexican adults
EMBERSON J. et al, (2025)
Author Correction: A deep catalogue of protein-coding variation in 983,578 individuals.
Sun KY. et al, (2025), Nature, 637
Complex relationship between Amerindian ancestry and obesity in the Mexican population.
Baca P. et al, (2025), Gac Med Mex, 161, 41 - 47
Cognitive impairment at older ages among 8000 men and women living in Mexico City: a cross-sectional analyses of a prospective study.
González-Carballo C. et al, (2024), BMC Public Health, 24